13 patents currently held
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2036. from the record
Of the 17 now held by other companies, 17 name Mayo Foundation for Medical Education and Research as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2036
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2036 · High confidence
Also notable
Ends no later than Jun 2039 · Low confidence
Also notable
Ends Dec 2038 · High confidence
Technology to Inhibit Vascular Changes That Lead to Vision Loss in the Eye
US 10,588,916
The most cited patent in this portfolio, cited by 9 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
US 10,981,892
A family of 6 related applications built on the 2021 grant. Protection runs to 2039. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
US 10,519,197
A family of 5 related applications built on the 2019 grant. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Jan 2035 · High confidence
The most cited patent in this portfolio, cited by 56 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 30, 2027The maintenance fee for Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer (US 10,519,197) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Methods of Inhibiting Pathological Angiogenesis (US 11,865,123) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Technology to Inhibit Vascular Changes That Lead to Vision Loss in the Eye (US 10,588,916) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Methods of Treating Retinal Vasculopathies (US 11,951,115) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,588,916 | Technology to Inhibit Vascular Changes That Lead to Vision Loss in the Eye In force · High confidence | In force | High confidence | |
| US 11,129,838 | Methods of Inhibiting Pathological Angiogenesis In force · High confidence | In force | High confidence | |
| US 11,865,123 | Methods of Inhibiting Pathological Angiogenesis In force · High confidence | In force | High confidence | |
| US 11,111,259 | Acylsulfonamide Derivatives for Treating Senescence-Associated Diseases and Disorders In force · High confidence | In force | High confidence | |
| US 10,519,197 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer In force · High confidence | In force | High confidence | |
| US 10,703,745 | Acyl Phosphonamidates and Acyl Benzylamines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,738,042 | Phosphonamidates that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,745,429 | Phospholidines that are Bcl Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated By Senescent Cells and for Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,717,722 | Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer In force · Medium confidence | In force | Medium confidence | |
| US 10,981,892 | Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 13: 17 patents in force now held by others · 11 patents ended · 4 applications pending · 30 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.